Physician profile
Semyon Faynboym
NPI 1215295548
$14,585.60
in general payments reported to CMS, 2019-2025
15 companies · $12K in 2025
The $12K reported for 2025 was more than what 93% of Pain Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $405).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $537 · 2021: $341 · 2022: $367 · 2023: $479 · 2024: $713 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,400 · Consulting Fee: $4,500 · Food and Beverage: $2,491 · Travel and Lodging: $908 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,400.00 |
| Consulting Fee | $4,500.00 |
| Food and Beverage | $2,490.87 |
| Travel and Lodging | $907.92 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $11,721.69 | 2024-2025 | Caplyta |
| Abbvie INC. | $869.15 | 2021-2025 | |
| Abbott Laboratories | $508.64 | 2019 | |
| Axsome Therapeutics, INC. | $321.97 | 2023-2025 | Auvelity |
| Bausch Health US, LLC | $312.76 | 2021-2025 | Aplenzin |
| Otsuka America Pharmaceutical, INC. | $235.82 | 2021-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $205.36 | 2021-2025 | Spravato |
| Takeda Pharmaceuticals U.S.A., INC. | $159.38 | 2023-2025 | Trintellix |
| Biogen, INC. | $70.05 | 2023 | |
| Harmony Biosciences LLC | $45.10 | 2022 | |
| Lundbeck LLC | $31.52 | 2025 | Rexulti |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $28.76 | 2025 | Rejoyn |
| Stryker Corporation | $28.10 | 2019 | |
| Noven Therapeutics, LLC | $23.82 | 2025 | Xelstrym |
| Collegium Pharmaceutical, INC. | $23.48 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Semyon Faynboym listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.